Kiniksa Pharmaceuticals International (KNSA) EBITDA (2017 - 2026)

Kiniksa Pharmaceuticals International's EBITDA history runs 10 years deep, the most recent figure standing at $29.3 million for Q1 2026.

• Quarterly EBITDA rose 120.52% year-over-year to $29.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.2 million (up 689.9% YoY) and the FY2025 annual result came in at $77.2 million, up 269.28% from the prior year.
• EBITDA was $29.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $19.8 million in the prior quarter.
• Across five years, EBITDA topped out at $46.4 million in Q3 2022 and bottomed at -$23.3 million in Q1 2022.
• A 5-year average of $2.7 million and a median of -$117000.0 in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2024 — EBITDA tumbled 23925.93% — and 2025, when it surged 17330.77%.
• Kiniksa Pharmaceuticals International's EBITDA stood at $6.0 million in 2022, then slumped by 98.66% to $81000.0 in 2023, then tumbled by 23925.93% to -$19.3 million in 2024, then soared by 202.43% to $19.8 million in 2025, then soared by 48.05% to $29.3 million in 2026.
• Business Quant data shows KNSA's EBITDA at $29.3 million in Q1 2026, $19.8 million in Q4 2025, and $24.0 million in Q3 2025.